Ken Griffin Guardant Health, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$22.3 - $36.29 $390,250 - $635,075	-17,500 Reduced 11.57%	133,700 $3.07 Million
Q2 2024 Aug 14, 2024	BUY	$16.07 - $31.84 $970,628 - $1.92 Million	60,400 Added 66.52%	151,200 $4.37 Million
Q1 2024 May 15, 2024	BUY	$17.13 - $26.91 $856,500 - $1.35 Million	50,000 Added 122.55%	90,800 $1.87 Million
Q4 2023 Feb 14, 2024	SELL	$21.58 - $29.5 $120,847 - $165,200	-5,600 Reduced 12.07%	40,800 $1.1 Million
Q3 2023 Nov 14, 2023	SELL	$25.8 - $39.97 $286,380 - $443,667	-11,100 Reduced 19.3%	46,400 $1.38 Million
Q2 2023 Aug 14, 2023	SELL	$20.94 - $38.01 $753,840 - $1.37 Million	-36,000 Reduced 38.5%	57,500 $2.06 Million
Q1 2023 May 15, 2023	SELL	$22.92 - $33.76 $2.05 Million - $3.02 Million	-89,500 Reduced 48.91%	93,500 $2.19 Million
Q4 2022 Feb 14, 2023	SELL	$25.44 - $59.78 $984,528 - $2.31 Million	-38,700 Reduced 17.46%	183,000 $4.98 Million
Q3 2022 Nov 14, 2022	BUY	$43.66 - $61.0 $7.1 Million - $9.92 Million	162,700 Added 275.76%	221,700 $11.9 Million

323

127M

844K

2.38M

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.34B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.